GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (NAS:URGN) » Definitions » Gross Margin %

UroGen Pharma (UroGen Pharma) Gross Margin % : 90.28% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is UroGen Pharma Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. UroGen Pharma's Gross Profit for the three months ended in Dec. 2023 was $21.24 Mil. UroGen Pharma's Revenue for the three months ended in Dec. 2023 was $23.53 Mil. Therefore, UroGen Pharma's Gross Margin % for the quarter that ended in Dec. 2023 was 90.28%.


The historical rank and industry rank for UroGen Pharma's Gross Margin % or its related term are showing as below:

URGN' s Gross Margin % Range Over the Past 10 Years
Min: -59.84   Med: 89.27   Max: 99.84
Current: 88.68


During the past 9 years, the highest Gross Margin % of UroGen Pharma was 99.84%. The lowest was -59.84%. And the median was 89.27%.

URGN's Gross Margin % is ranked better than
83.67% of 735 companies
in the Biotechnology industry
Industry Median: 59.4 vs URGN: 88.68

UroGen Pharma had a gross margin of 90.28% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for UroGen Pharma was 0.00% per year.


UroGen Pharma Gross Margin % Historical Data

The historical data trend for UroGen Pharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UroGen Pharma Gross Margin % Chart

UroGen Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only - 91.45 89.27 88.11 88.68

UroGen Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 87.49 86.83 88.44 88.65 90.28

Competitive Comparison of UroGen Pharma's Gross Margin %

For the Biotechnology subindustry, UroGen Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UroGen Pharma's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's Gross Margin % falls into.



UroGen Pharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

UroGen Pharma's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=73.4 / 82.713
=(Revenue - Cost of Goods Sold) / Revenue
=(82.713 - 9.361) / 82.713
=88.68 %

UroGen Pharma's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=21.2 / 23.53
=(Revenue - Cost of Goods Sold) / Revenue
=(23.53 - 2.286) / 23.53
=90.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


UroGen Pharma  (NAS:URGN) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

UroGen Pharma had a gross margin of 90.28% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


UroGen Pharma Gross Margin % Related Terms

Thank you for viewing the detailed overview of UroGen Pharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


UroGen Pharma (UroGen Pharma) Business Description

Traded in Other Exchanges
Address
400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.
Executives
Jason Drew Smith officer: General Counsel C/O UROGEN PHARMA LTD., 400 ALEXANDER PARK DRIVE, PRINCETON NJ 08540
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
Mark Schoenberg officer: Chief Medical Officer C/O UROGEN PHARMA LTD., 9 HA TA ASIYA STREET, RA ANANA L3 4365007
Daniel George Wildman director 12520 SUNNYDALE DRIVE, WELLINGTON FL 33414
Leana Wen director C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Dong Kim officer: Chief Financial Officer C/O UROGEN PHARMA, LTD., 400 ALEXANDER PARK DRIVE, 4TH FLOOR, PRINCETON NJ 08540
Elizabeth A. Barrett officer: Chief Executive Officer C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Molly Henderson officer: Chief Financial Officer 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Peter P. Pfreundschuh officer: CFO C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Stephen Mullennix officer: COO C/O UROGEN PHARMA LTD, 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Stuart Holden director C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Cynthia M Butitta director 3165 PORTER DRIVE, PALO ALTO CA 94304
Ron Bentsur director, officer: Chief Executive Officer 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Fred E Cohen director 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102